2,3,4-substituted-cyclopentanones as therapeutic agents

Details for Australian Patent Application No. 2005309605 (hide)

Owner Allergan, Inc.

Inventors Donde, Yariv; Holobiski, Mark; Posner, Mari F.; Burk, Robert M.; Garst, Michael E.

Agent Davies Collison Cave

Pub. Number AU-B-2005309605

PCT Pub. Number WO2006/058063

Priority 10/997,039 23.11.04 US

Filing date 21 November 2005

Wipo publication date 1 June 2006

Acceptance publication date 23 August 2012

International Classifications

C07C 405/00 Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins

A61K 31/5575

A61P 27/06 Drugs for disorders of the senses

C07D 333/16 Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom

C07D 333/62 Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom

Event Publications

14 June 2007 PCT application entered the National Phase

  PCT publication WO2006/058063 Priority application(s): WO2006/058063

23 August 2012 Application Accepted

  Published as AU-B-2005309605

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005309606-Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

2005309601-Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject